Sign in
CompletedNo phase

Cellular Reprogramming-Enhanced Skin Grafting for Diabetic Foot Ulcers

Key facts

Who runs it
Hu Zhicheng
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
108 people enrolled
Started
1 Aug 2017
Ended
30 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • autologous skin cell
  • skin graft
Record updated
18 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • .Adults aged ≥18 years with type 1 or type 2 diabetes mellitus, diagnosed according to WHO criteria
  • .Presence of a chronic diabetic foot ulcer located below the ankle, classified as Wagner grade 2-3, with a post-debridement area of 5-80 cm²
  • .Target ulcer present for ≥4 weeks and unhealed despite ≥4 weeks of standard wound care prior to randomization
  • .HbA1c <12%, measured at screening or within 3 months prior to randomization
  • .Any revascularization of the affected limb completed ≥4 weeks before randomization
  • .Ability to provide written informed consent and comply with all study procedures and follow-up requirements

Who cannot take part

  • .Revascularization of the affected limb planned or performed within 4 weeks prior to randomization
  • .Participation in another interventional clinical trial within 3 months prior to randomization
  • .Active infection of the target ulcer requiring systemic antibiotics, or presence of non-removable necrosis, purulence, or sinus tracts
  • .Significant peripheral arterial disease, defined as ABI <0.7 or >1.3
  • .Active malignancy, uncontrolled autoimmune disease, or current use of systemic immunosuppressive therapy
  • .Hematologic disorders that may impair wound healing
  • .HIV infection or active hepatitis
  • .Any condition that, in the investigator's judgment, could impair informed consent, protocol compliance, patient safety, or data reliability
  • .End-stage renal disease or eGFR <20 mL/min/1.73 m²
  • .Pregnancy, lactation, or intention to become pregnant during the study period

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Diabetic foot ulcer is one of the refractory wounds and always poses many challenges in clinical practice. This study was conducted to have a prospective, randomised, controlled study compare the safety and efficacy of the autologous skin cell with skin graft (experiment group) with split-thickness skin graft (STSG, control group) alone on treating diabetic foot ulcers.

The 2 groups in the trial

  • autologous skin cellTreatment being tested

    autologous skin cell with skin graft

  • skin graftExisting treatment, for comparison

    split-thickness skin graft as control group

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intraoperative Cellular Reprogramming-Enhanced Skin Transplantation for Diabetic Foot Ulcers: A Randomized Clinical Trial
Record updated
18 February 2026